HR Execs on the Move

Maruho Medical

www.maruho-medical.com

 
We are focused on improving sports medicine outcomes by providing innovative technologies and supporting surgeons with integrity, collaboration, and a commitment to excellence. We achieve this by providing medical devices and services that are unique, highly effective, reliable, easy to learn and cost-effective. At present, maruho medical offers a comprehensive portfolio of orthopedic surgery products that complement arthroscopic shoulder, knee, hip, and extremity procedures.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.maruho-medical.com
  • 3005 Chastain Meadows Parkway NW Suite 300
    Marietta, GA USA 30066
  • Phone: 888.404.3980

Executives

Name Title Contact Details
Bret Schwartzhoff
Senior Vice President of Sales and Marketing Profile

Similar Companies

Taro Pharmaceuticals (HQ)

"Taro Pharmaceuticals U.S.A., Inc., and its divisions, subsidiaries and affiliates (collectively, ""Taro"") operate a variety of websites designed to provide you with services ranging from valuable health resources to corporate news and product information"

PharMEDium Healthcare Corporation

PharMEDium is an organization that has established an outstanding reputation for quality and customer service in the healthcare marketplace. Credit for this goes to everyone in the organization. We hope you, too, will find satisfaction and take pride in

Total Care Rx

Total Care RX serves as an extension of the patient’s medical team to monitor medication compliance, provide education and offer other value-added services not offered by retail pharmacies.

Syntiron

Syntiron LLC is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has four product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome. GCS-100 is La Jolla’s first-in-class galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010, La Jolla’s second-generation galectin-3 inhibitor, is a more potent and purified derivative of GCS-100 that can be delivered orally for the potential treatment of nonalcoholic steatohepatitis and other diseases characterized by tissue fibrosis. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hemochromatosis and beta thalassemia